Experiments using EMT-6 (breast cancer), CT26 (colon cancer), and 3LL (murine T cells) tumor syngeneic mouse models showed that YM101 has superior anti-tumor activity compared to anti-TGF-β and anti-PD-L1 monotherapies. This evidence concerns the gene TGFB1 and neoplasm.